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Abstract
Background: In order to maximize the useful therapeutic life of antimalarial drugs, it is crucial to understand the mechanisms
by which parasites resistant to antimalarial drugs are selected and spread in natural populations. Recent work has demonstrated
that pyrimethamine-resistance conferring mutations in Plasmodium falciparum dihydrofolate reductase (dhfr) have arisen rarely de
novo, but spread widely in Asia and Africa. The origin and spread of mutations in Plasmodium vivax dhfr were assessed by
constructing haplotypes based on sequencing dhfr and its flanking regions.
Methods: The P. vivax dhfr coding region, 792 bp upstream and 683 bp downstream were amplified and sequenced from 137
contemporary patient isolates from Colombia, India, Indonesia, Papua New Guinea, Sri Lanka, Thailand, and Vanuatu. A repeat
motif located 2.6 kb upstream of dhfr was also sequenced from 75 of 137 patient isolates, and mutational relationships among
the haplotypes were visualized using the programme Network.
Results: Synonymous and non-synonymous single nucleotide polymorphisms (SNPs) within the dhfr coding region were
identified, as was the well-documented in-frame insertion/deletion (indel). SNPs were also identified upstream and downstream
of dhfr, with an indel and a highly polymorphic repeat region identified upstream of dhfr. The regions flanking dhfr were highly
variable. The double mutant (58R/117N) dhfr allele has evolved from several origins, because the 58R is encoded by at least 3
different codons. The triple (58R/61M/117T) and quadruple (57L/61M/117T/173F, 57I/58R/61M/117T and 57L/58R/61M/117T)
mutant alleles had at least three independent origins in Thailand, Indonesia, and Papua New Guinea/Vanuatu.
Conclusion: It was found that the P. vivax dhfr coding region and its flanking intergenic regions are highly polymorphic and that
mutations in P. vivax dhfr that confer antifolate resistance have arisen several times in the Asian region. This contrasts sharply
with the selective sweep of rare antifolate resistant alleles observed in the P. falciparum populations in Asia and Africa. The finding
of multiple origins of resistance-conferring mutations has important implications for drug policy.
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Background
In order to maximize the useful therapeutic life of antima-
larial drugs, it is crucial to understand the mechanisms by
which parasites resistant to antimalarial drugs are selected
and subsequently spread in natural populations. This is a
major issue in Plasmodium falciparum, where resistance to
two safe, inexpensive drugs, chloroquine and sulphadox-
ine-pyrimethamine, has spread widely in endemic areas
(for review see [1,2]). Chloroquine has been the drug of
choice for Plasmodium vivax for decades, but resistance has
been reported in several areas of south-east Asia, and the
spread of these resistant strains has serious implications
for public health [3]. While sulphadoxine-pyrimethamine
is not generally recommended as a treatment for P. vivax,
in many regions P. vivax is sympatric with P. falciparum [4-
6]. Due to presumptive treatment for P. falciparum, misdi-
agnosis or mixed-species infection, P. vivax populations
are sometimes inadvertently exposed to sulphadoxine-
pyrimethamine pressure. Thus, study of the resistance to
pyrimethamine in P. vivax can be a very useful tool to
understand the evolution of resistance in these parasite
populations.
Point mutations in the gene that encodes dihydrofolate
reductase (DHFR) confer resistance to pyrimethamine in
both P. vivax and P. falciparum, and mutant alleles have
been identified in most endemic regions (for review see
[1,7-9]). In P. falciparum, non-synonymous single nucle-
otide polymorphisms (SNPs) that alter the amino acids
within the active site of the enzyme at residues 50, 51, 59,
108 and 164 have been demonstrated both in vitro and in
vivo to confer resistance to pyrimethamine [1]. Studies of
the P. vivax dhfr gene have associated changes at amino
acids 49, 57, 58, 61, 117 and 173 with pyrimethamine
resistance (for review see [8]). Not surprisingly, most of
these amino acid changes are also located at similar posi-
tions, as compared to P. falciparum, within the active site
for the P. vivax enzyme. A recent study conducted in India
has found that mutations in P. vivax dhfr and P. falciparum
dhfr are correlated, and that resistance-conferring muta-
tions in P. vivax dhfr are more common in areas where P.
falciparum is the major Plasmodium species and where sul-
phadoxine-pyrimethamine usage is highest. These find-
ings strongly suggest that sulphadoxine-pyrimethamine
used to treat P. falciparum exerts substantial selective pres-
sure on P. vivax populations, providing a selective advan-
tage to parasites bearing resistance-conferring mutations
in P. vivax dhfr [10].
Despite these similarities between the two systems, there
are some striking differences. Most important, the P. vivax
dhfr gene is highly polymorphic. Over 20 different alleles
of the dhfr coding region have been identified from a lim-
ited geographic sampling and insertions/deletions
(indels) and synonymous and non-synonymous changes
are common (for review see [8]). In contrast, only a hand-
ful of P. falciparum dhfr alleles have been identified from
far more extensive surveillance, and insertions/deletions
and non-synonymous changes are exceedingly rare (for
review see [7]). Thus, the mutation set seen in P. vivax dhfr
is substantially more diverse than that seen in P. falci-
parum dhfr. It is important to acknowledge that due to dif-
ficulties with in vitro culture of P. vivax our knowledge of
the impact of mutations in dhfr on resistance to pyrimeth-
amine has been derived from yeast and bacterial transfec-
tion systems and from a limited number of trials in
human subjects (for review see [7]). This means that defi-
nition of true in vivo and in vitro resistance-conferring dhfr
alleles is somewhat challenging and controversial.
Several groups have assessed the origin and spread of
resistance-conferring mutations in P. falciparum dhfr by
assessing microsatellites flanking the gene [11-17].
Remarkably, the highly resistant triple-mutant P. falci-
parum dhfr allele in Africa shares a common origin with
dhfr alleles bearing two to four mutations in Southeast
Asia [17]. In contrast, these loci show high levels of varia-
tion around sensitive dhfr alleles. Thus, mutations that
confer pyrimethamine resistance have arisen de novo
extremely rarely in P. falciparum and most resistant alleles
in Asian and African populations are identical by descent,
indicative of a selective sweep of this allele in these popu-
lations.
However, recent work has suggested that the common tri-
ple mutant allele of dhfr may have arisen independently in
Kenyan populations of P. falciparum [12]. Furthermore, it
has been found in South America that a triple mutant
allele of P. falciparum dhfr arose on a haplotype different
from that observed in Southeast Asia and Africa [11].
Recently one group has attempted to examine the evolu-
tion of resistance-conferring mutations in P. vivax dhfr by
assessing microsatellites positioned 38.83 and 230.64 kb
upstream of dhfr and 6.15 kb and 283.28 kb downstream
[18]. These microsatellite loci were found to be highly
polymorphic, with expected heterozygosity ranging from
0.50 to 0.82. However, there was no association between
mutations in P. vivax dhfr and the flanking microsatellites.
It may be speculated that this lack of association may have
been due, in part, to the great distance between the
assessed microsatellites and the gene. For these microsat-
ellites to have hitchhiked along with the dhfr gene selec-
tion would have had to have been extremely strong and
quite recent, with little recombination occurring to break
down associations and little mutation of microsatellites
[19]. Given these stipulations, it may not be surprising
that there was no association between the flanking micro-
satellites and P. vivax dhfr.Malaria Journal 2008, 7:72 http://www.malariajournal.com/content/7/1/72
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In any case, not all drug pressure has produced dramatic
selective sweeps of the P. falciparum population. The point
mutations in the cytochrome b1 gene that confer resistance
to the atovaquone component of Malarone®  have
occurred repeatedly and independently [20]. The
increased copy number that confers resistance to meflo-
quine also appears to have been selected in multiple inde-
pendent sites, even within the small area of Southeast Asia
where the drug has been intensively used [14,21]. Thus,
the selective sweep paradigm may not apply to resistance
to all antimalarial drugs even in P. falciparum.
Given the differences in diversity of P. vivax dhfr alleles as
compared to P. falciparum, it cannot be assumed that P.
vivax will follow the pattern of selective sweep generally
observed for P. falciparum dhfr. To address this question,
in this paper the origin and spread of resistance-conferring
mutations in P. vivax dhfr are assessed.
Materials and methods
Orientation to Plasmodiumvivax dhfr-ts
The P. vivax genome was recently sequenced by The Insti-
tute for Genomic Research (TIGR) [22]. 3,306 bp lie
between P. vivax dhfr-ts and the nearest upstream ORF,
and 880 bp lie between P. vivax dhfr-ts and the nearest
downstream ORF; there are no introns.
Sample sources and DNA extraction
Genomic DNA was extracted from filter paper blotted
with the blood of patients infected with P. vivax (Qiagen,
Rockville MD). P. vivax dhfr and 792 bp upstream/683 bp
downstream were amplified and sequenced from 137
contemporary patient isolates (Colombia, n = 9; India, n
= 24; Indonesia, n = 43; Papua New Guinea, n = 7; Sri
Lanka, n = 16; Thailand, n = 29; Vanuatu, n = 9) and from
the MR4 repository, we assessed samples from Panama
(1966), Nicaragua (pre-1986), Pakchong (Thailand,
1972), and ONG (Vietnamese refugee who had spent
time in Indonesia, collected 1980) [23,24]. Amplification
of Indian isolates was performed within India, and ampli-
cons were sent to the United States for sequencing.
The region further upstream of P. vivax dhfr, to 3,258 bp
upstream, was amplified and sequenced from a subset of
75 of the 137 patient isolates (Colombia, n = 7; Indonesia,
n = 24; Sri Lanka, n = 13; Papua New Guinea, n = 7; Thai-
land, n = 17; Vanuatu, n = 7) and from the 4 MR4 isolates
described above. In addition, ts was sequenced from 19
patient isolates (Colombia, n = 8; Indonesia, n = 4; Thai-
land, n = 7).
The Colombian samples were collected from Urabá, on
the western coast of Colombia, in 2005. The Indonesian
samples are derived from two locations, Papua (n = 29) in
1996 to 1999 and Java (n = 14) in 2000, which are sepa-
rated by approximately 3,200 km. The Thai samples are
derived from the Thai/Cambodian border (n  = 6) and
from the Thai/Myanmar border (n = 23) in 2005. The Sri
Lankan samples are derived from the north of the island
(n = 12), and the south (n = 3) in 2003; in addition, there
is one Sri Lankan isolate whose geographic origin is
unknown. The Indian isolates are derived from Nadiad,
Gujarat (n = 6), Delhi (n = 11), Chennai, Tamilnadu (n =
4), and Goa (n = 3) and were collected during 2003 to
2005. The Vanuatu isolates are from Malo Island in 2005
(n = 9). The Papua New Guinea isolates are from East New
Britain Province in 1989 (n = 2), from an unknown loca-
tion passaged through Aotus monkey, collected 1989 (n =
1), and from Lae in 2006 (n = 4).
All isolates were derived from studies that had been
approved by the appropriate local Institutional Review
Board and these anonymous samples are in the exempt
category of the University of Washington Human Subjects
Review Board.
Table 1: Primers for amplification and sequencing of Pvdhfr-ts and flanking, using PCR product A (amplifies P. vivax dhfr-ts and 792 bp 
upstream, 683 bp downstream). All sequences are written 5' to 3'
Primer name Use Sequence
S1048 PCR A 1st nested TGA ACA GCC AAG CGA ATA GGT AAA A
S1049 PCR A 1st nested ATT TGA AGG TTA AAA TGG GGT GAC G
S1105 PCR A 2nd nested/sequencing ATG CAC ACA TCT TCG CTC TC
S1106 PCR A 2nd nested/sequencing TCT TTT TCA CGT TCG CTG TG
S303 Sequencing ATG GAG GAC CTT TCA GAT GTA TT
S1090 Sequencing AAA AAA ATA TGC ACT CCC CAT TT
S1092 Sequencing ACT TTT ATA GCT AGC TAG CGA AGT GTT
S1166 Sequencing TTT TCT TCG CGG CGA CAA
S1088 Sequencing CAG TTA TAT GCA CAC ATC TTC GC
S1095 Sequencing ACT GCG GAC AGC GCT TCG
S1096 Sequencing TGA AGA TTA AGC AGC ACC CAG
S1098 Sequencing ATG GCT TTA CCT CCT TGT CAMalaria Journal 2008, 7:72 http://www.malariajournal.com/content/7/1/72
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Amplification of Pvdhfr and flanking region (Product A: 
792 bp upstream to 683 bp downstream)
A nested PCR protocol was used. Primer sequences are
given in Table 1. For the first-round amplification of Pvd-
hfr and flanking, 0.2 µL FailSafe enzyme (Epicentre Tech-
nologies, Madison WI), 1 µL each 20 µM S1048 and
S1049, 2 µL genomic DNA, 10 µL FailSafe buffer E, and
water were combined to a total volume of 20 µL. The PCR
protocol uses modified hotstart, in which reactions are
transferred to the PCR machine only when the machine
has reached 94C. For both first and second round ampli-
fications the same protocol was used: 94C, 3 min, fol-
lowed by 5 cycles of 94C: 30 sec, 67C: 45 sec, 72C: 3 min
25 sec; 5 cycles of 94C: 30 sec, 65C: 45 sec, 72C: 3 min 25
sec; 5 cycles of 94C: 30 sec, 63C, 45 sec, 72C, 3 min 25 sec;
3 cycles of 94C: 30 sec, 61C: 45 sec, 72C, 3 min 25 sec; 3
cycles of 94C: 30 sec, 59C: 45 sec, 72C: 3 min 25 sec; 3
cycles of 94C: 30 sec, 57C: 45 sec, 72C, 3 min 25 sec; 5
cycles of 94C: 30 sec, 55C: 45 sec, 72C, 3 min 25 sec, with
a final extension at 72C: 5 min.
For the second-round amplification of Pvdhfr and flank-
ing, 1 µL FailSafe enzyme (Epicentre Technologies, Madi-
son WI), 5 µL each 20 µM S1105 and S1106, 10 µL 1st
nested product (used without any clean-up), 50 µL Fail-
Safe buffer E, and water were combined to a total volume
of 100 µL. Products were cleaned with the GeneClean kit
(Qbiogene, Solon OH), following manufacturer's instruc-
tions; products were quantified by running 5 µL Gene-
Cleaned product on a 0.7% ethidium bromide-stained
agarose gel.
Amplification further upstream of Plasmodium vivax dhfr 
(Product B: 420 bp upstream to 3258 bp upstream)
A nested PCR protocol was used. Primer sequences are
given in Table 2. For the first-round amplification of the
region further upstream of Pvdhfr, 0.2 µL FailSafe enzyme
(Epicentre Technologies, Madison WI), 1 µL each 20 µM
S1238 and S1239, 2 µL genomic DNA, 10 µL FailSafe
buffer E, and water were combined to a total volume of 20
µL. The PCR protocol uses the same modified hotstart
procedure as above. For both first and second round
amplifications the same protocol was used: 94C, 3 min,
followed by 5 cycles of 94C: 30 sec, 67C: 45 sec, 72C: 3
min; 5 cycles of 94C: 30 sec, 65C: 45 sec, 72C: 3 min; 5
cycles of 94C: 30 sec, 63C, 45 sec, 72C, 3 min; 3 cycles of
94C: 30 sec, 61C: 45 sec, 72C, 3 min; 3 cycles of 94C: 30
sec, 59C: 45 sec, 72C: 3 min; 3 cycles of 94C: 30 sec, 57C:
45 sec, 72C, 3 min; 5 cycles of 94C: 30 sec, 55C: 45 sec,
72C, 3 min, with a final extension at 72C: 5 min.
For the second-round amplification of Pvdhfr and flank-
ing, 1 uL FailSafe enzyme (Epicentre Technologies, Madi-
son WI), 5 µL each 20 µM S1259 and S1240, 10 µL 1st
nested product (used without any clean-up), 50 µL Fail-
Safe buffer E, and water were combined to a total volume
of 100 µL. PCR products were cleaned and quantified as
above.
Sequencing
Sequencing was performed using an ABI capillary
sequencer (AppliedBiosystems Foster City CA), and dou-
ble coverage with independent primers was used (Tables
1 and 2). Sequences were aligned and analysed with
Sequencher (Gene Codes, Ann Arbor MI). Insertions and
deletions were hand verified. Sequences were aligned with
the Sal I reference sequence recently sequenced by TIGR
[22].
Data analysis
The freely available programme Network was used to gen-
erate median joining networks [25]. To aid in generation
of Network diagrams, sequences were aligned with the
commercially available programme DNA Alignment ver-
Table 2: Primers for amplification and sequencing of Pvdhfr-ts and flanking, using PCR product B (amplifies the region from -3258 bp 
upstream to -420 bp upstream of P. vivax dhfr-ts). All sequences are written 5' to 3'
Primer name Use Sequence
S1238 PCR 1st nested ATC AAG GAA GGC AGA CTC CA
S1239 PCR 1st nested AGC GTA CTG CCG TCG AAA TA
S1259 PCR 2nd nested, sequencing GCC TGG TTA CTT TTG GTG GA
S1240 PCR 2nd nested, sequencing AAA AAC TGA GGC CAC ATT CG
S1241 sequencing ACT TCT CTC CTG GGC AGA CTT
S1242 sequencing GAG AGT TGG TAA TGC GGG G
S1243 sequencing CAT GGC TGG GGA AGG CTC
S1244 sequencing CCC TTA ACC CGC ATG CAC
S1245 sequencing CTC CCC CCA TGG GAC AAA AA
S1246 sequencing TTT GAT TTG ATT TGA TTT GAT TTG A
S1247 sequencing ATG CCA CAG GGA AGT TAC AG
S1248 sequencing CAT TTT TCA CAT TTT GGA AA
S1249 sequencing CCT CGC GCG GGG GGG AAA
S1250 sequencing TGC TGC AAT GCA AGT GGG TMalaria Journal 2008, 7:72 http://www.malariajournal.com/content/7/1/72
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sion 1.1.3.0 (Fluxus Engineering, Suffolk England).
Briefly, the median joining network allows visualization
of the mutational paths that may have led to the observed
data; haplotypes are linked based on the assumption that
mutations are more likely to derive from a more frequent
haplotype and proceed to a less frequent haplotype. In
interpreting network diagrams, circles represent haplo-
types; the diameter of the circle is proportional to the
number of isolates represented. The length of lines linking
haplotypes is proportional to the number of mutational
steps separating haplotypes. Nodes (black circles) repre-
sent hypothetical ancestral haplotypes linking the pres-
ently extant haplotypes, or may represent haplotypes that,
though presently extant, were not sampled.
The Network diagram is especially helpful when trying to
determine whether multiple haplotypes of a given dhfr
allele are the result of independent origins or of mutations
accumulating on an already established haplotype. In the
case where multiple haplotypes of a given dhfr allele are
present as a result of independent mutations, the haplo-
types will appear far from one another on the Network
diagram, separated by a large number of mutational steps.
In the case where multiple haplotypes of a given dhfr allele
are present as a result of mutations accruing on one
genetic background (i.e. there is one origin of the allele of
interest, with additional polymorphisms accumulating
over time), the haplotypes will cluster, and will be sepa-
rated by a limited number of mutational steps.
For the presented Network diagram, 139 sequences, from
792 bp upstream to 683 bp downstream (PCR product A),
were included. All 4 MR4 isolates were included, as well as
135 of the 137 patient isolates, for a total of 139
sequences. The two patient isolates not included in the
presented Network diagram are described below. The Net-
work programme was designed to compare sequences that
differ only by SNPs, and a multi-nucleotide indel region
was identified upstream of dhfr, and another multi-nucle-
otide indel was identified within the dhfr coding region.
To accommodate these differences in the programme,
both of these indels were coded as an insertion of a single
nucleotide relative to the wildtype sequence, and pre-
sented in the Network diagram in that way. There were
five indel types for the upstream indel, and four indel
types for the indel within dhfr. Because one upstream
indel type was carried by a single parasite (Sri Lankan iso-
late with synonymous mutation in codon 69 and
upstream indel type E), this isolate was dropped from the
Network diagram. Thus, only four upstream indel types
were considered. For entering sequences into Network,
the actual sequence of the inserted or deleted region was
recoded as wildtype; all other polymorphisms were left as
is. Sequences with neither an upstream indel nor an indel
within dhfr were left as is, while those with an upstream
indel had the nucleotide A, G, T or C, to represent
upstream indels A, B, C, and D, respectively, appended to
the end of their upstream sequence. Sequences with an in-
frame indel in dhfr had the nucleotide A, G, T or C, to rep-
resent indels 1, 2, 3 and 4, respectively, appended to the
beginning of their dhfr sequence. Sequences with both an
upstream and in-frame indel had one nucleotide
appended to the end of their upstream sequence, and one
nucleotide appended to the beginning of their dhfr
sequence as described above. This coding system was used
because indels are likely to be the result of the appearance
or disappearance of large segments of DNA as a unit, not
by addition or subtraction of one nucleotide at a time. By
entering sequence data with indels coded as the insertion
of a single nucleotide relative to the wildtype sequence,
the Network software more accurately portrays the rela-
tionships between alleles.
In addition, for the presented Network diagram, one
Indonesian quadruple mutant (the isolate wildtype at
nucleotide 581 upstream of dhfr) was excluded. This iso-
late was excluded from the Network diagram because its
inclusion created a spurious link between the Papua New
Guinean quadruple mutants and the remainder of the
Indonesian quadruple mutants. With this Indonesian
quadruple mutant included in the dataset, the generated
Network diagram is identical to that presented herein
except that there is a bridge between the Papua New Gui-
nean quadruple mutants and the Indonesian quadruple
mutants.
Results and Discussion
Plasmodium vivax dhfr-ts
Previous studies of the coding region of P. vivax dhfr have
demonstrated considerable genetic diversity among the
many pyrimethamine-resistant alleles (for review see [8]).
This observation suggested that the diversity might origi-
nate from multiple origins, rather than the very few foci
observed among pyrimethamine-resistant alleles of P. fal-
ciparum dhfr [11-17]. Because of the relative scarcity of
microsatellites in the P. vivax genome, we chose to
sequence P. vivax dhfr and the flanking intergenic region,
and to construct haplotypes based on sequence data. Pvd-
hfr and its flanking regions (792 bp upstream to 683 bp
downstream) were sequenced from a geographically
diverse set of isolates (Figure 1). Pvdhfr is encoded by the
N-terminal domain of the bifunctional gene that also
encodes thymidylate synthase [26]. At the outset of the
study, the entire dhfr-ts gene was sequenced. No polymor-
phisms were identified in the ts coding region or linker,
sequenced from a subset of diverse isolates (n = 19), and
so DNA sequences of these domains were not further
studied. The diversity within and surrounding the dhfr-ts
locus provided the polymorphisms needed to begin toMalaria Journal 2008, 7:72 http://www.malariajournal.com/content/7/1/72
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The dhfr and flanking region haplotypes of contemporary global isolates (n = 120) and MR4 samples (n = 4), with each row indi- cating one distinct haplotype and the number of isolates with that haplotype Figure 1
The dhfr and flanking region haplotypes of contemporary global isolates (n = 120) and MR4 samples (n = 4), with 
each row indicating one distinct haplotype and the number of isolates with that haplotype. Only polymorphic positions are 
included; blue cells indicate identity with the TIGR reference. The figure is divided vertically into thirds: the region upstream of 
P. vivax dhfr, dhfr itself, and the region downstream of dhfr. Numerals in the first row indicate the position of the polymorphic 
nucleotide relative to dhfr ('-' refers to positions upstream of dhfr, '+' refers to positions downstream of dhfr). For the upstream 
indel region, a: deletion of bases [-710, -677], b: deletion of bases [-729, -679], c: deletion of bases [-710, -694], d: insertion of 
17 bases after nucleotide -675 (act ggg ggg aaa tgc tc), e: deletion of bases [-746, -696]. Within dhfr, the 4 letters within a single 
column refer to the amino acids at positions 57, 58, 61 and 117. For the indel within the dhfr coding region, 1: deletion of 
codons 98–103, 2: deletion of codons 93–98, 3: insertion of 18 nucleotides between wildtype codons 98 and 99 (agc ggt ggt gac 
aac aca), 4: insertion of 18 bp between codons 99 and 100 (tgg tga caa cac aag cgg). Within dhfr, the numerals 69, 93 and 199 
refer to synonymous or non-synonymous changes at those codons. If the nucleotide mutation yielding 58R is not indicated, the 
change is 174G. The Thai 57L/58R/61M/117T alleles carry A at nucleotide 171, while the Thai 57I/58R/61M/117T alleles carry 
A at nucleotide 171 and A at nucleotide 169. Countries are abbreviated as follows: Colombia (Col), Indonesia (Indo), Nicara-
gua (Nic), Panama (Pan), Papua New Guinea (PNG), Sri Lanka (SL), Thailand (Thai), Vanuatu (Van), Vietnam (Viet).
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Indo (3) A G FRTN TTT
Indo (2) A G FRTN
Indo (5) C T T G FRTN A
Indo (1) D G FRTN
Van (1) B G G FRTN 2
Van (1) B G LRTT 2 F
Van (3) A G FRMT 2
Van (3) B G FRMT 2
Van (1) ND G FRMT 2
Indo (7) A A G LRMT TTT
Indo (3) A A G LRMT 2 TTT
Indo (1) ND A G LRMT 2 TTT
Indo (1) A G LRMT 2
PNG (1) A A G LRMT 3
PNG (4) A G LRMT 3
PNG (1) B G LRMT 3
Thai (3) A G LRMT T
Thai (17) A G IRMT TMalaria Journal 2008, 7:72 http://www.malariajournal.com/content/7/1/72
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infer whether the pyrimethamine-resistant alleles of P.
vivax also show a signature of a selective sweep.
In order to present a logical framework for this complex
dataset, the haplotypes of isolates wildtype at dhfr codons
57, 58, 61 and 117 will be presented first, followed by iso-
lates with progressively more mutated dhfr alleles. Non-
synonymous changes in these four codons will be exam-
ined first because they have been shown to specify key
amino acids in pyrimethamine-resistance. Of the total
141 isolates examined, 32 isolates carried an allele
wildtype at these positions. Among these isolates the dhfr
coding region contained both synonymous and non-syn-
onymous mutations as well as four distinct in-frame
indels, abbreviated 1 through 4 in Figure 1, and described
in the figure legend. The flanking regions of these alleles
carried a variety of single nucleotide polymorphisms
(SNPs). All isolates assessed in this study differed from the
TIGR reference by the substitution of a G for an A at nucle-
otide 245 upstream of P. vivax dhfr. A highly polymorphic
indel region upstream of dhfr, abbreviated as A through E
in Figure 1, was also identified. All together there were 14
extended haplotypes carried by the 32 isolates wildtype at
codons 57, 58, 61 and 117.
The alleles mutant at codons 57, 58, 61 and 117 are
arranged in Figure 1 according to increasing numbers of
non-synonymous SNPs in the coding region. Four isolates
carried the 117N allele, with two distinct haplotypes. Four
isolates carried an allele that encoded 57L/58R, but two
different nucleotide substitutions encoded the leucine at
codon 57. The Sri Lankan isolates bearing the 57L/58R
allele had an adenine at nucleotide 171, while the 57L/
58R Papua New Guinean isolate carried a cytosine at that
position. Based on the differences in the dhfr  coding
region, including the in-frame indel, and the flanking
intergenic region, it is clear that in this dataset we have
identified two origins of the 57L/58R allele.
Previous work had documented a double mutant allele,
58R/117N, that is widely disbursed in South Asia (for
review see [8]) and 54 of the isolates in the present study
carried an allele that encoded this amino acid combina-
tion. Thirteen haplotypes were observed in this group,
including alleles with 3 different nucleotide changes that
all specify an arginine at codon 58. Forty two of these iso-
lates specified the 58R with a guanine at nucleotide 174;
these came from a variety of locations in India, Java and
Papua Indonesia, the Thai/Cambodian border and the
Thai/Myanmar border, and one isolate from Vanuatu.
Three isolates from Papua Indonesia had an adenine at
nucleotide 174, and the isolates from Colombia were
unique with a cytosine at nucleotide 172. This convergent
evolution is likely to reflect selection pressure of
pyrimethamine on these isolates. Based on these Pvdhfr
coding region differences and on the flanking polymor-
phisms, the overall diversity of Pvdhfr  is considerably
higher than that observed in double mutant alleles of Pfd-
hfr.
The major goal of this study was to examine whether
highly pyrimethamine-resistant alleles of Pvdhfr  have
arisen in many locations or, like P. falciparum, appear to
have a limited number of origins. To answer this question,
the haplotype pattern of the highly mutant triple and
quadruple mutant Pvdhfr  alleles are of most interest.
Seven isolates from Vanuatu that carried a triple mutant
allele, 58R/61M/117T, were identified. These isolates had
identical dhfr coding regions, but differed in the upstream
indel region. One isolate from Vanuatu carried a novel
quadruple mutant 57L/58R/117T/173F allele, with the 57
leucine encoded by a cytosine at nucleotide 171, but with
a haplotype in the flanking regions similar to the 58R/
61M/117T triple mutants.
Isolates that encoded the 57L/58R/61M/117T or 57I/58R/
61M/117T allele were identified from three locations:
Indonesian Papua, Papua New Guinea and western Thai-
land. Based on differences in both coding and flanking
regions, there appear to be several distinct origins of these
quadruple mutant alleles, as well. Eleven of 12 Indone-
sian quadruple mutants share identical upstream and
downstream flanking sequences: a G to A mutation at
nucleotide 581 upstream of dhfr and an insertion of three
thymines at nucleotide 383 downstream of dhfr. All Indo-
nesian quadruple mutants carried a cytosine at nucleotide
169; four of these isolates also have an in-frame indel
within dhfr (listed as 2 in Figure 1). One Indonesian quad-
ruple mutant isolate had a unique haplotype and carried
neither the SNP at 581 upstream nor the TTT insertion
downstream of dhfr.
The 57L/58R/61M/117T allele was observed in 3 Thai iso-
lates; the 57 leucine was encoded by an adenine at nucle-
otide 171. The remaining 17 Thai quadruple mutants
carried the 57I/58R/61M/117T allele, with adenines at
nucleotides 169 and 171. All of these Thai quadruple
mutant isolates shared a common haplotype different
from that characteristic of the Indonesian quadruple
mutant isolates.
Finally, the Papua New Guinean isolates with a quadruple
mutant allele have a cytosine at nucleotide 171, yielding
the 57L. All six isolates have similar flanking haplotypes,
but differ in that one PNG quadruple mutant carries
upstream indel B while the others carry upstream indel A.
In addition, one isolate carries a SNP at nucleotide 581
upstream. Quadruple mutant alleles from Papua New
Guinea dating from 1989 and 2006 were assessed; isolates
from each time-point contained nearly identical flankingMalaria Journal 2008, 7:72 http://www.malariajournal.com/content/7/1/72
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regions, suggesting that this particular quadruple mutant
haplotype was well established in 1989 and continued to
be prevalent through 2006.
To better visualize the relationships among these varied
alleles of Pvdhfr, the data set was analysed using the Net-
work programme described in detail in the Methods sec-
tion. The diagram in Figure 2 summarizes this analysis.
Inspection of the diagram allows several inferences to be
drawn. First, the wild type alleles (in blue) mostly cluster
together, reflecting the various SNPs and common indels
by which they differ. The wide spread 58R/117N double
mutant alleles (in green) show a more dispersed pattern,
suggesting that they have several origins. This is under-
lined by the three different nucleotide changes that all
convergently encode the 58R amino acid. The triple
mutant allele, 58R/61M/117T (in grey) was observed only
in Vanuatu, and these cluster together, along with the
Vanuatu 57L/61M/117T/173F allele (in yellow).
The patterns of relatedness among the quadruple mutants
are most interesting. There are three clusters, reflecting
apparent origins of the allele that encodes the 57L(I)/58R/
61M/117T enzyme in Indonesia, Thailand and Papua
New Guinea. The Thai haplotypes differ only in the non-
synonymous SNP that changes codon 57 from leucine to
isoleucine, and cluster tightly as expected. The quadruple
mutant alleles from PNG also cluster together; these iso-
lates also cluster with the triple and quadruple mutants
from Vanuatu. The Indonesian quadruple mutant isolates
cluster together clearly separate from the Thai and PNG/
Vanuatu groups. These data support strongly the inference
that highly pyrimethamine resistant alleles of Pvdhfr have
arisen in the Southeast Asian region independently. In the
present sample set there are three distinct origins of iso-
lates bearing the highly pyrimethamine-resistance confer-
ring 117T allele, with origins in Thailand, Indonesia, and
PNG/Vanuatu.
These extensive differences have been identified within a
rather small genetic region, the 792 bp upstream and 683
bp downstream of the Pvdhfr-ts coding region. To examine
a somewhat more distant locus, a highly polymorphic
repeat motif comprised of (TTAAA)1 (TCAAA)n(TTAAA)n
(TGAAA)n that follows a string of 25 adenines in the TIGR
reference sequence at nucleotide position -2608 upstream
of the Pvdhfr coding region was assessed. The sequence of
this region from a subset of isolates (data not shown) was
determined. Figure 3 shows the 5' repeat motif and
upstream, downstream and dhfr  genotypes for isolates
with the triple or quadruple mutant dhfr alleles, as well as
for isolates in which recombination appears to have
occurred. Colors in the dhfr genotype column reflect dhfr
genotype, as in Figure 1. Colors upstream and down-
stream of dhfr reflect similarity of flanking regions. A vari-
ety of 5' repeat types were found, and the degree of
recombination occurring between the 5' repeat region and
the dhfr gene was examined. For example, it was found
that substantial recombination upstream of dhfr  has
occurred among the isolates from Vanuatu; to a lesser
extent recombination upstream of dhfr is seen among the
isolates from PNG. Recombination has occurred
upstream of dhfr in one Thai isolate bearing the 57I/58R/
61M/117T allele (row 2). This isolate shares the 5' repeat
motif with Thai isolates bearing the 58R/117N allele (row
1). There is one unusual Indonesian quadruple mutant
allele whose 5' repeat motif is unlike those from the other
Indonesian quadruple mutants (row 9), and is more sim-
ilar to the 5' repeat motifs seen in isolates from Vanuatu
(row 10). The 5' repeat motif carried by the Indonesian
quadruple mutants differed from that seen in the Thai
quadruple mutants, and these in turn differed from the
repeat motifs carried by the PNG and Vanuatu triple and
quadruple mutants. In conclusion, this additional
sequencing of the 5' repeat motif bolsters the finding that
highly mutant Pvdhfr alleles have arisen multiple times.
Not only are differences in the dhfr  coding region
observed, but differences in the upstream and down-
stream flanking regions, and in the 5' repeat, are evi-
denced as well.
The prevalence of mutations in P. vivax dhfr was also
assessed by geographic region (Figure 4). Isolates from
Papua New Guinea and Vanuatu are not included in this
figure because they were part of this study specifically
because they carried highly mutant dhfr. The four isolates
obtained through MR4 are also not included. In the
present sample set, triple and quadruple mutant dhfr alle-
les were identified only in isolates from Papua Indonesia,
Papua New Guinea, Vanuatu and the Thai/Myanmar bor-
der.
In conclusion, highly pyrimethamine-resistant Pvdhfr alle-
les appear to have arisen three times, with origins in Thai-
land, Indonesia, and PNG/Vanuatu, and their diversity is
dramatically higher than that seen in P. falciparum. The
contrast in these parameters suggests that drug resistance
may arise and spread very differently in the two species.
The isolates included in the present study came princi-
pally from Asia. Within this relatively small number of
samples, three distinct origins of alleles bearing the 117
threonine mutation that is associated, in concert with
mutations in other codons, with very high resistance to
pyrimethamine were identified (for review see [8]). More-
over, isolates that express the same amino acid sequence
of some very common double mutant alleles differ in the
codons that encode the residue. Presumably this reflects
very strong convergent evolution of the resistant enzyme.
In contrast, in P. falciparum the two common doubleMalaria Journal 2008, 7:72 http://www.malariajournal.com/content/7/1/72
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Network diagram of P. vivax dhfr and flanking Figure 2
Network diagram of P. vivax dhfr and flanking. Note that only haplotypes with more than one isolate are included in the 
diagram. Coloured circles represent dhfr and flanking haplotypes; lines represent mutational steps connecting haplotypes, and 
black nodes represent hypothetical ancestral haplotypes or haplotypes present in the population but not sampled. Colour cod-
ing is as follows: wildtype, blue; 58R/117N, green; 117N, orange; 57L/58R, pink; 57L/61M/117T/173F, yellow; 58R/61M/117T, 
grey; 57I(L)/58R/61M/1117T, red. Note the wide separation between the Thai and Indonesian quadruple mutant alleles, and the 
triple and quadruple mutants from PNG and Vanuatu.
 
 
Thai 57L(171A)/58R/61M/117T 
and 57I(171A, 169A)/58R/61M/117T 
PNG 57L(171C)/58R/61M/117T 
Indonesian 
57L(169C)/58R/61M/117T 
Vanuatu 58R/61M/117T 
Vanuatu 57L(171C)/61M/117T/173F Malaria Journal 2008, 7:72 http://www.malariajournal.com/content/7/1/72
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5' repeat motif, upstream flanking region, dhfr genotype and downstream flanking region of selected isolates Figure 3
5' repeat motif, upstream flanking region, dhfr genotype and downstream flanking region of selected isolates. 
Numbers in columns 2 through 9 indicate the number of repeats of a given type, with the first repeat beginning 2,608 bp 
upstream of dhfr per the reference sequence. Colours in the dhfr genotype column reflect dhfr genotype, as in Figure 3. Col-
ours upstream and downstream of dhfr reflect similarity of flanking regions. The 5' indel and in-frame indel within dhfr are 
coded as in Figure 3. All isolates bear the 174G mutation in codon 58.
Country (n) TTAAA TCAAA TTAAA TTAAG TTAAA TGAAA TTAAA TGAAA 5' indel 5' SNPs dhfr genotype 3' SNPs
Thailand (6) 1 4 1 1 4 4 A 58R/117N
Thailand (1) 1 4 1 1 4 4 A 57I(171A,169A)/58R/61M/117T +223T
Thailand (1) 1 5 9 7 A 57I(171A,169A)/58R/61M/117T +223T
Thailand (1) 1 6 8 7 A 57I(171A,169A)/58R/61M/117T +223T
Thailand (5) 1 6 9 7 A 57I(171A,169A)/58R/61M/117T +223T
Thailand (2) 1 6 9 7 A 57I(171A,169A)/58R/61M/117T +223T
Indonesia (5) 1 3 5 1 1 2 A -581A 57L(169C)/58R/61M/117T +383 insert TTT
Indonesia (2) 1 3 5 1 1 2 A -581A 57L(169C)/58R/61M/117T/indel 2 +383 insert TTT
Indonesia (1) 1 9 4 4 A 57L(169C)/58R/61M/117T/indel 2 +383 insert TTT
Vanuatu (1) 1 9 4 4 B -633G 58R/117N/indel 2
Vanuatu (2) 1 6 4 4 A 58R/61M/117T/indel 2
Vanuatu (1) 1 6 4 4 B 58R/61M/117T/indel 2
Vanuatu (1) 1 8 4 4 A 58R/61M/117T/indel 2
Vanuatu (1) 1 8 4 4 B 58R/61M/117T/indel 2
Vanuatu (1) 1 6 4 4 B 57L(171C)/58R/117T/173F/indel 2 
PNG (1) 1 5 5 6 A 57L(171C)/58R/indel 3
PNG (2) 1 5 7 4 A 57L(171C)/58R/61M/117T/indel3
PNG (1) 1 5 7 4 A -581A 57L(171C)/58R/61M/117T/indel3
PNG (1) 1 5 7 4 B 57L(171C)/58R/61M/117T/indel3
PNG (1) 1 5 6 4 A 57L(171C)/58R/61M/117T/indel3
PNG (1) 1 8 4 4 A 57L(171C)/58R/61M/117T/indel3
Distribution of P. vivax dhfr alleles by region Figure 4
Distribution of P. vivax dhfr alleles by region. Note that indels are not considered. Isolates from Papua New Guinea and 
Vanuatu are excluded because they were included in this study specifically because they carry highly mutant dhfr alleles; isolates 
obtained from MR4 were also excluded.
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mutant dhfr alleles have arisen a few times, but the nucle-
otide sequences that encode the amino acid changes at
residue 51 or 59 are the same. Most striking, the highly
pyrimethamine-resistant triple mutant allele has arisen
only rarely in P. falciparum [13,16]. Thus, the very wide
selective sweep of a few resistant alleles that characterizes
Pfdhfr does not seem to be the pattern for Pvdhfr.
What factors could explain the discrepancy between the
frequency with which highly mutant alleles arise in Pfdhfr
versus Pvdhfr? First, it is important to note that the paucity
of origins of highly mutant Pfdhfr was unexpected. Given
the intrinsic mutation rate of approximately 1.6 × 10-4/
locus/generation [27], and assuming that roughly 108 to
1012 parasites may reside within a single patient, muta-
tions in dhfr would be expected to arise de novo in every
patient. For example, a study combining in vitro culture of
P. falciparum under pyrimethamine pressure and mathe-
matical modeling found a mutation rate of 2.5 × 10-9
mutations/dhfr  gene/replication, though they assessed
only two codons for non-synonymous substitutions [28].
It may be possible that differences in the frequency with
which resistance-conferring mutations arise and spread in
Pvdhfr versus Pfdhfr are due to differences in the mutation
rates of the parasite species. However, it is not currently
possible to assess this hypothesis, as experimentally deter-
mined P. vivax mutation rate and recombination rate are
unknown. This study highlights that P. vivax and P. falci-
parum are different in important ways, notably that the
origin and spread of drug resistance may not occur in the
same manner in these two species. In addition, as sul-
phadoxine-pyrimetamine is not generally used intention-
ally to combat P. vivax parasites, the level of drug pressure
exerted against parasites of this species is likely quite vari-
able. This variable drug pressure may have an impact on
the speed with which resistance-conferring mutations in
P. vivax dhfr arise and are propagated through the popula-
tion.
Other work has outlined important differences in the
basic biology of P. vivax and P. falciparum. For example, P.
vivax has a latent hypnozoite stage in the liver, in which
relapses may occur months or even years following the
primary infection; P. falciparum does not have this charac-
teristic. In addition, gametocytogenesis is quite different
in the two species, with the P. falciparum sexual cycle
delayed with respect to the asexual cycle. In addition, P.
vivax gametocytes at all stages of development are suscep-
tible to drugs that kill asexual stage parasites, while only
P. falciparum stage 1–3 gametocytes are susceptible to
most antimalarials (for review see [29]). It is important to
conduct additional studies to understand the biological
basis for the finding that drug resistance-conferring muta-
tions in dhfr have arisen and spread in a different manner
in P. vivax versus P. falciparum.
In the present study quadruple mutant P. vivax dhfr alleles
were assessed from Indonesia, Thailand and PNG. Mutant
dhfr alleles containing the highly pyrimethamine-resist-
ance conferring 117 threonine mutation were assessed
from Vanuatu. Two alleles were identified: 58R/61M/
117T and 57L/61M/117T/173F, and these alleles cluster
with the quadruple mutant alleles from Papua New
Guinea. Thus, the highly mutant dhfr alleles found in this
study (those including the 117T mutation in concert with
mutations in other codons) have arisen three times, with
origins in Thailand, Indonesia, and PNG/Vanuatu. It will
be of great future interest to assess the haplotyes of highly
mutant P. vivax alleles from additional locales in order to
determine the global diversity of these alleles. This study
reveals a heavy antifolate selection on the P. vivax popula-
tion even though the drugs have not been recommended
for the treatment of infections of this species. Thus, the
results also reflect the very high exposure of P. vivax to sul-
phadoxine-pyrimethamine, and reveal a major factor con-
tributing to the development and spread of drug
resistance.
In conclusion, the present study describes the origin and
dissemination of highly mutant P. vivax dhfr alleles.
Importantly, the pattern of selective sweep generally evi-
denced in P. falciparum was not observed; rather, inde-
pendent mutations are common. Understanding the
means by which mutations in P. vivax dhfr arise and
spread may have important implications for malaria con-
trol policy [30]. Further, it is important to understand
gene flow among P. vivax populations in order to predict
how resistance to other drugs, for which molecular mark-
ers do not yet exist, may spread.
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